Ranking Profile - Apellis Pharmaceuticals Inc

Introduction

Apellis Pharmaceuticals Inc (Apellis) is a clinical-stage biopharmaceutical company that focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases through inhibition of the complement system at the level of C3 (central protein). Its pipeline product portfolio includes EMPAVELI pegcetacoplan injection for paroxysmal nocturnal hemoglobinuria disease and SYFOVRE intravitreal pegcetacoplan injection for Geographic Atrophy. Its other products include APL-1030, APL-2006 and Orala Alternative Pathway Inhibitor, among others. The company conducts research on chronic therapy with a C3 inhibitor into clinical trialsIt operates in Australia, Bermuda, the US, Germany, France, Ireland, the Netherlands, Switzerland, the UK nad Cayman Islands. Apellis is headquartered in Waltham, Massachusetts, the US.